罗欣药业“加减法”：拟6756万元收购盈利子公司，上月欲剥离亏损资产

Core Viewpoint - The company, Luoxin Pharmaceutical, plans to acquire a 19.0526% stake in Beijing Health Technology from Chengdu Deyi for 67.56 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1][7] Group 1: Acquisition Details - The acquisition is classified as a related party transaction since Chengdu Deyi and its concerted parties hold more than 5% of the company's shares [1][7] - Beijing Health serves as the sales and promotion platform for Luoxin's main products, focusing on drug wholesale and promotion [1][7] - The registered capital of Beijing Health has increased from 33.33 million yuan to 353.6 million yuan over time, with Luoxin's stake decreasing before this acquisition [1][7] Group 2: Financial Performance of Beijing Health - For the period from January to October 2025, Beijing Health reported revenues of 638.71 million yuan, a 16.12% increase from the full-year revenue of 550.05 million yuan in 2024 [3][9] - The net profit for the same period was 81.85 million yuan, marking a turnaround from previous losses, with positive cash flow from operating activities of 19.79 million yuan [3][9] Group 3: Luoxin Pharmaceutical's Financial Overview - In the first three quarters of 2025, Luoxin's revenue was 1.723 billion yuan, a decrease of 8.37% year-on-year, while the net profit attributable to shareholders was 22.93 million yuan, an increase of 108.64% [11] - The company reported a significant increase in cash flow from operating activities, amounting to 280 million yuan, a 272.42% rise compared to the previous year [11] - Luoxin anticipates a narrowed loss for the full year 2025, projecting a net profit of approximately -340 million to -250 million yuan [12]